Biomerica Cash Conversion Cycle from 2010 to 2026

BMRA Stock  USD 2.38  0.01  0.42%   
Biomerica's Cash Conversion Cycle is decreasing over the years with slightly volatile fluctuation. Overall, Cash Conversion Cycle is expected to go to 147.34 this year. From 2010 to 2026 Biomerica Cash Conversion Cycle quarterly data regression line had arithmetic mean of  191.26 and r-squared of  0.22. View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
126.78
Current Value
147.34
Quarterly Volatility
52.87044876
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Biomerica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomerica's main balance sheet or income statement drivers, such as Depreciation And Amortization of 213.8 K, Interest Expense of 32.2 K or Selling General Administrative of 5 M, as well as many indicators such as Price To Sales Ratio of 1.44, Dividend Yield of 0.0 or PTB Ratio of 1.46. Biomerica financial statements analysis is a perfect complement when working with Biomerica Valuation or Volatility modules.
  
Build AI portfolio with Biomerica Stock
Check out the analysis of Biomerica Correlation against competitors.
For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.
Analyzing Biomerica's Cash Conversion Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Cash Conversion Cycle has evolved provides context for assessing Biomerica's current valuation and future prospects.

Latest Biomerica's Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of Biomerica over the last few years. It is Biomerica's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomerica's overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Slightly volatile
   Cash Conversion Cycle   
       Timeline  

Biomerica Cash Conversion Cycle Regression Statistics

Arithmetic Mean191.26
Geometric Mean181.37
Coefficient Of Variation27.64
Mean Deviation41.25
Median201.64
Standard Deviation52.87
Sample Variance2,795
Range207
R-Value(0.47)
Mean Square Error2,332
R-Squared0.22
Significance0.06
Slope(4.89)
Total Sum of Squares44,725

Biomerica Cash Conversion Cycle History

2026 147.34
2025 126.78
2024 140.86
2023 222.48
2022 177.07
2021 53.55
2020 222.01

About Biomerica Financial Statements

Biomerica stakeholders use historical fundamental indicators, such as Biomerica's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although Biomerica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biomerica's assets and liabilities are reflected in the revenues and expenses on Biomerica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biomerica. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Conversion Cycle 126.78  147.34 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:
Check out the analysis of Biomerica Correlation against competitors.
For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. Projected growth potential of Biomerica fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biomerica assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.53)
Revenue Per Share
2.009
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.41)
Return On Equity
(0.70)
Understanding Biomerica requires distinguishing between market price and book value, where the latter reflects Biomerica's accounting equity. The concept of intrinsic value—what Biomerica's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biomerica's price substantially above or below its fundamental value.
It's important to distinguish between Biomerica's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomerica should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomerica's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.